Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 6/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.53 |
| ▸ | BCL2 | P10415 | 1/20 | 0.47 |
| ▸ | KAT6A | Q92794 | 2/20 | 0.46 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.44 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30988817 | 1.00 | GSK3B (0.53) | GSK3BPTPN1BCL2KAT6ASMYD3 | |
| SCHEMBL29256511 | 0.88 | GSK3B (0.49) | GSK3BPTPN1BCL2KAT6ASMYD3 | |
| SCHEMBL5052377 | 0.86 | GSK3B (0.50) | GSK3BPTPN1KAT6ACYP4F2CYP4A11 | |
| SCHEMBL29256507 | 0.86 | GSK3B (0.50) | GSK3BPTPN1CNR2LOXL2CYP4F2 | |
| SCHEMBL3033628 | 0.85 | BCL2 (0.50) | BCL2KAT6ASMYD3CNR2LOXL2 | |
| SCHEMBL684561 | 0.83 | GSK3B (0.55) | GSK3BPTPN1SMYD3CNR2CYP4F2 | |
| SCHEMBL27588759 | 0.83 | GSK3B (0.55) | GSK3BPTPN1LOXL2FOLH1 | |
| SCHEMBL924897 | 0.83 | CYP4F2 (0.49) | BCL2KAT6ASMYD3CNR2LOXL2 | |
| SCHEMBL7860030 | 0.83 | CYP4F2 (0.49) | GSK3BPTPN1CYP4F2CYP4A11 | |
| SCHEMBL8099947 | 0.82 | BCL2 (0.51) | BCL2KAT6ASMYD3CNR2LOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118340754-B | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-119490387-A | Compounds for the treatment of pain-related diseases | 源道医药(苏州)有限公司 | 2025-02-21 | — | — | CN | disclosed |
| EP-3800186-B1 | CYANOPYRROLIDINES AS DUB INHIBITORS FOR THE TREATMENT OF CANCER | MISSION THERAPEUTICS LTD (GB) | 2024-10-02 | — | — | EP | disclosed |
| CN-118340754-A | Compound for treating heart failure and related diseases and application thereof | 源道医药(苏州)有限公司 | 2024-07-16 | — | — | CN | disclosed |
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | MISSION THERAPEUTICS LIMITED (GB) | 2022-05-03 | — | — | US | disclosed |
| WO-2017214505-A1 | CERAMIDE GALACTOSYLTRANSFERASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2017-12-14 | — | — | WO | disclosed |
| EP-2758380-B1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | disclosed |
| US-9073881-B2 | Benzoic acid derivatives | HOFFMANN-LA ROCHE INC. (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2758380-A1 | BENZOIC ACID DERIVATIVES AS EIF4E INHIBITORS | F.HOFFMANN-LA ROCHE AG (CH) | 2014-07-30 | — | — | EP | disclosed |
| CN-103958487-A | Benzoic acid derivatives as eif4e inhibitors | HOFFMANN LA ROCHE | 2014-07-30 | — | — | CN | disclosed |
| WO-2002057261-A2 | DIAMINOTHIAZOLES AND THEIR USE AS INHIBITORS OF CYCLIN-DEPENDENT KINASE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-07-25 | — | — | WO | disclosed |
| EP-0736509-B1 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL CO (JP) | 2001-11-14 | — | — | EP | disclosed |
| US-6156940-A | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY, LIMITED (JP) | 2000-12-05 | — | — | US | disclosed |
| US-6025531-A | REACTING A PROCHIRAL KETONE WITH A MIXTURE BORON-CONTAINING COMPOUNDS HAVING A BORANE REACTION PRODUCT FROM OPTICALLY ACTIVE BETA-AMINOALCOHOL AND A BORON HYDRIDE OR A METAL BOROHYDRIDE, AND AN OPTICALLY ACTIVE OXAZABOROLIDINE | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-02-15 | — | — | US | disclosed |
| EP-0713848-B1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS COMPANY (JP) | 1999-09-08 | — | — | EP | disclosed |
| US-5831132-A | REDUCING AGENT FROM BORANES AND AMINO ALCOHOLS | SUMIKA FINE CHEMICALS COMPANY, LTD. (JP) | 1998-11-03 | — | — | US | disclosed |
| US-5801280-A | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1998-09-01 | — | — | US | disclosed |
| EP-0736509-A2 | Processes for preparing optically active alcohols and optically active amines | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1996-10-09 | — | — | EP | disclosed |
| EP-0713848-A1 | Process for producing optically active carbinols | SUMIKA FINE CHEMICALS Company, Limited (JP) | 1996-05-29 | — | — | EP | disclosed |
| US-4033978-A | Thiacycl[2.2.2]azine carboxylic acids | SYNTEX (U.S.A.) INC. (US) | 1977-07-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319287-B2 | Cyanopyrrolidines as dub inhibitors for the treatment of cancer | USP30, USP39, UCHL1 | GSK3B 3368/4885PTPN1 1436/4885BCL2 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.